# A Phase III Study Comparing Taletrectinib With Standard Therapy in ROS1 Positive Locally Advanced or Metastatic Non-small Cell Lung Cancer Patients

Source: https://onco.cc/trials/nct06564324/  
OnCo record `nct06564324` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 3 trial of Taletrectinib, Crizotinib in non-small-cell lung cancer and small-cell lung cancer, run by Nuvation Bio Inc., now recruiting.

## Summary

A Phase III Study Comparing Taletrectinib With Standard Therapy in ROS1 Positive Locally Advanced or Metastatic Non-small Cell Lung Cancer Patients is a phase 3 interventional study registered as NCT06564324 by Nuvation Bio Inc., with 194 participants planned, started 2024-11-27 and due to reach its primary completion in 2029-01. Interventions recorded: Taletrectinib, Crizotinib. Conditions listed: Non Small Cell Lung Cancer. No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-16
- Tags: ctgov-ingest
- Registry id: NCT06564324
- Phase: 3
- Setting: A Phase 3 Multicenter Open-label Study of Taletrectinib Versus a Standard of Care ROS1-Tyrosine Kinase Inhibitor (Crizotinib) in TKI-Naïve Patients With ROS1-Positive Locally Advanced or Metastatic Non-Small Cell Lung Cancer (TRUST-III)
- Sponsor: Nuvation Bio Inc.
- Enrolled: 194

## Sources

- ClinicalTrials.gov NCT06564324: https://clinicaltrials.gov/study/NCT06564324

## Connected records

- cancers: [Non-small-cell lung cancer](https://onco.cc/cancers/nsclc/), [Small-cell lung cancer](https://onco.cc/cancers/sclc/)
- drugs: [Crizotinib](https://onco.cc/drugs/crizotinib/), [Taletrectinib](https://onco.cc/drugs/taletrectinib/)
- companies: [Nuvation Bio](https://onco.cc/companies/nuvation-bio/)

---
JSON: https://onco.cc/api/v1/entities/nct06564324.json